Cargando…
Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma
The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gela...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662371/ https://www.ncbi.nlm.nih.gov/pubmed/26640367 http://dx.doi.org/10.2147/DDDT.S86075 |
_version_ | 1782403153667293184 |
---|---|
author | Chen, Yi-Dan Liang, Zhong-Yuan Cen, Yan-Yan Zhang, He Han, Mei-Gui Tian, Yun-Qiao Zhang, Jie Li, Shu-Jun Yang, Da-Sheng |
author_facet | Chen, Yi-Dan Liang, Zhong-Yuan Cen, Yan-Yan Zhang, He Han, Mei-Gui Tian, Yun-Qiao Zhang, Jie Li, Shu-Jun Yang, Da-Sheng |
author_sort | Chen, Yi-Dan |
collection | PubMed |
description | The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics. |
format | Online Article Text |
id | pubmed-4662371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46623712015-12-04 Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma Chen, Yi-Dan Liang, Zhong-Yuan Cen, Yan-Yan Zhang, He Han, Mei-Gui Tian, Yun-Qiao Zhang, Jie Li, Shu-Jun Yang, Da-Sheng Drug Des Devel Ther Original Research The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics. Dove Medical Press 2015-11-20 /pmc/articles/PMC4662371/ /pubmed/26640367 http://dx.doi.org/10.2147/DDDT.S86075 Text en © 2015 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Chen, Yi-Dan Liang, Zhong-Yuan Cen, Yan-Yan Zhang, He Han, Mei-Gui Tian, Yun-Qiao Zhang, Jie Li, Shu-Jun Yang, Da-Sheng Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title | Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title_full | Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title_fullStr | Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title_full_unstemmed | Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title_short | Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
title_sort | development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662371/ https://www.ncbi.nlm.nih.gov/pubmed/26640367 http://dx.doi.org/10.2147/DDDT.S86075 |
work_keys_str_mv | AT chenyidan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT liangzhongyuan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT cenyanyan developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT zhanghe developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT hanmeigui developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT tianyunqiao developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT zhangjie developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT lishujun developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma AT yangdasheng developmentoforaldispersibletabletscontainingprednisolonenanoparticlesforthemanagementofpediatricasthma |